Literature DB >> 26869860

Botulinum Toxin in the Treatment of Pediatric Upper Limb Spasticity.

Aloysia L Schwabe1.   

Abstract

Botulinum neurotoxin (BoNT) is one of the mainstays in the treatment of pediatric spasticity and dystonia. When considering initiation of BoNT treatment for spasticity, treatment goals and responses to prior conservative measures such as passive range of motion exercises, splinting, and other medication trials should be reviewed. As a general rule, children should be engaged in therapy services around the time of the injections and have a robust home program in place. When managing spasticity in children with BoNT injections, the practitioner should be well versed in functional anatomy with specialized training in injection techniques. Localization techniques in addition to anatomical landmarks are recommended for improved efficacy and include limited electromyography, electrical stimulation, and/or ultrasound guidance. A follow-up visit for the purpose of reassessment during the peak effect of the drug is advised. It is known that BoNT is effective at reducing spasticity and improving range of motion, but it remains to be determined to what degree this translates into improved function, activity, and participation.

Entities:  

Keywords:  botulinum toxin; cerebral palsy; neurotoxin; spasticity

Year:  2016        PMID: 26869860      PMCID: PMC4749377          DOI: 10.1055/s-0036-1571302

Source DB:  PubMed          Journal:  Semin Plast Surg        ISSN: 1535-2188            Impact factor:   2.314


  17 in total

1.  Spasticity causes a fundamental rearrangement of muscle-joint interaction.

Authors:  Richard L Lieber; Jan Fridén
Journal:  Muscle Nerve       Date:  2002-02       Impact factor: 3.217

2.  Meta-analysis of neutralizing antibody conversion with onabotulinumtoxinA (BOTOX®) across multiple indications.

Authors:  Markus Naumann; Alastair Carruthers; Jean Carruthers; Sheena K Aurora; Ross Zafonte; Susan Abu-Shakra; Terry Boodhoo; Mary Ann Miller-Messana; George Demos; Lynn James; Frederick Beddingfield; Amanda VanDenburgh; Mary Ann Chapman; Mitchell F Brin
Journal:  Mov Disord       Date:  2010-10-15       Impact factor: 10.338

3.  Botulinum toxin injection as an adjunct when planning hand surgery in children with spastic hemiplegia.

Authors:  I Autti-Rämö; A Larsen; J Peltonen; A Taimo; L von Wendt
Journal:  Neuropediatrics       Date:  2000-02       Impact factor: 1.947

4.  Accuracy of muscle localization without EMG: implications for treatment of limb dystonia.

Authors:  F M Molloy; H A Shill; A Kaelin-Lang; B I Karp
Journal:  Neurology       Date:  2002-03-12       Impact factor: 9.910

Review 5.  Botulinum treatment of spasticity: why is it so difficult to show a functional benefit?

Authors:  G L Sheean
Journal:  Curr Opin Neurol       Date:  2001-12       Impact factor: 5.710

6.  Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity.

Authors:  Edward M Goldstein
Journal:  J Child Neurol       Date:  2006-03       Impact factor: 1.987

7.  Systemic adverse events following botulinum toxin A therapy in children with cerebral palsy.

Authors:  Krishant Naidu; Katherine Smith; Mary Sheedy; Brooke Adair; Xavier Yu; H Kerr Graham
Journal:  Dev Med Child Neurol       Date:  2010-02       Impact factor: 5.449

Review 8.  Spasticity associated with cerebral palsy in children: guidelines for the use of botulinum A toxin.

Authors:  L Andrew Koman; Beth Paterson Smith; Rajesh Balkrishnan
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

9.  Use of botulinum toxin type A in the management of patients with neurological disorders: a national survey.

Authors:  Nicola Smania; Carlo Colosimo; Anna Rita Bentivoglio; Giorgio Sandrini; Alessandro Picelli
Journal:  Funct Neurol       Date:  2013 Oct-Dec

Review 10.  Classification and definition of disorders causing hypertonia in childhood.

Authors:  Terence D Sanger; Mauricio R Delgado; Deborah Gaebler-Spira; Mark Hallett; Jonathan W Mink
Journal:  Pediatrics       Date:  2003-01       Impact factor: 7.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.